Comparable stake leader
Wei-Wu He
SEC ownership of CASI Pharmaceuticals, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001962738.
Disclosed value leader
Panacea Innovation Ltd
Comparable rows
9/9
Latest evidence
30 Jun 2026
- Public ticker
- CASIF on OTC
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Wei-Wu He
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
9 of 9
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Wei-Wu He
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001962738
- Issuer location
- Beijing, China
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of CASI Pharmaceuticals, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Wei-Wu He
Disclosed value leader
Panacea Innovation Ltd
Comparable rows
9/9
Latest evidence
30 Jun 2026
13D/G
3/4/5
13F
Lead comparable stake: 59%
13D/G row: Wei-Wu He
Showing 1-8 of 9 holder rows.
Quick read
Wei-Wu He leads the comparable SEC ownership view at 59%.
9 of 9 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Wei-Wu He's linked filing trail.
Comparable ownership
Top 5
Wei-Wu He
59%
Panacea Innovation Ltd
22%
James Huang
14%
Zhenfeng M. Chen
11%
Venrock Healthcare Capital Partne...
9.2%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 9 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Wei-Wu He |
13D/G
3/4/5
WEI-WU HE, Ph.D. · Director, 10%+ Owner
|
59%
|
$3,118,120
23,985,535 shares
|
+$650,000 | 18 May 2026 |
| Panacea Innovation Ltd |
13D/G
James Huang
|
22%
|
$4,698,042
4,651,527 shares
|
+$999,856 | 16 Dec 2025 |
| James Huang |
13D/G
3/4/5
Director
|
14%
|
$3,177,509
2,161,571 shares
|
$0 | 30 Jun 2025 |
| Zhenfeng M. Chen |
13D/G
Chen Zhenfeng
|
11%
|
$4,150,370
2,255,636 shares
|
$0 | 30 Sep 2025 |
| Venrock Healthcare Capital Partners III, L.P. |
13D/G
|
9.2%
|
$2,066,749
1,987,259 shares
|
$0 | 31 Dec 2025 |
| SPARKLE BYTE LTD |
13D/G
|
5%
|
$775,088
1,019,852 shares
|
$0 | 30 Sep 2025 |
| Ho Chi Sing |
13D/G
Zhou Quan
|
4.8%
|
$754,405
992,638 shares
|
$0 | 30 Sep 2025 |
| Alex Wu |
3/4/5
Director
|
0.08%
|
$29,042
34,168 shares
|
— | 18 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 20 Sep 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-11 of 11 reporting-owner rows connected to CASI Pharmaceuticals, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
11
Largest Forms 3/4/5 holder
James Huang
Net 12M change
$0
Latest report
18 Mar 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| James Huang | Director | $1,087,189 | Mixed | 18 Mar 2026 | ||
| Wei-Wu He | Director, 10%+ Owner | $611,566 | Mixed | 18 Mar 2026 | ||
| Alex Wu | Director | $29,042 | Mixed | 18 Mar 2026 | ||
| Barbara Krebs-Pohl | Director | Mixed | 18 Mar 2026 | |||
| Alexander A. Zukiwski | Global Chief Medical Officer | Mixed | 18 Mar 2026 | |||
| Chunhua Wang | Chief Operating Officer | Mixed | 18 Mar 2026 | |||
| Hai Huang | Global Chief Commercial Ofcr | Mixed | 18 Mar 2026 | |||
| Kun Qian | Global Controller | Mixed | 18 Mar 2026 | |||
| Wei R. Gao | General Counsel | Mixed | 18 Mar 2026 | |||
| Xuebo Zeng | Director | Mixed | 18 Mar 2026 | |||
| Thomas Folinsbee | Director | Mixed | 18 Mar 2026 |
Recent insider transactions for CASI Pharmaceuticals, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Alex Wu | CASIF | Ordinary Share | 0 | 34,168 | 18 Mar 2026 | Direct | ||||
| Wei-Wu He | CASIF | Ordinary Share | 0 | 637,644 | 18 Mar 2026 | See Footnote | ||||
| Wei-Wu He | CASIF | Ordinary Share | 0 | 100,000 | 18 Mar 2026 | See Footnote | ||||
| Wei-Wu He | CASIF | Ordinary Share | 0 | 300,000 | 18 Mar 2026 | See Footnote | ||||
| Wei-Wu He | CASIF | Ordinary Share | 0 | 753,234 | 18 Mar 2026 | See Footnote | ||||
| Wei-Wu He | CASIF | Ordinary Share | 0 | 44,107 | 18 Mar 2026 | See Footnote | ||||
| Wei-Wu He | CASIF | Ordinary Share | 0 | 1,910,550 | 18 Mar 2026 | Direct | ||||
| James Huang | CASIF | Ordinary Shares | 0 | 4,529,956 | 18 Mar 2026 | See Footnote |
* marks a reported price that did not pass the local price check.